A global study, led by UCL and UCLH, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer patients who were not able to be treated with ...
Jul 6, 2023
1
45
A blood-based tumor biomarker can predict the benefit of immunotherapy to patients with non-small cell lung cancer, according to a study published in Nature Medicine.
May 23, 2022
0
61
A new publication by Yale Cancer Center highlights recent breakthrough therapies developed to treat non-small cell lung cancer (NSCLC). The goal of the study is to provide views on how basic science advances will impact clinical ...
Aug 12, 2021
0
331
Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80 percent of all lung cancer cases. Despite the aggressive nature of NSCLC, circulating tumor cells that lead to metastases ...
Mar 9, 2021
0
32
The survival rates for patients with non-small cell lung cancer (NSCLC) have improved greatly over the past decade thanks to several new targeted treatment options for patients. However, lung cancer still remains the number ...
Mar 26, 2020
0
163
Non-small cell lung cancer (NSCLC) is the most commonly diagnosed cancer, and the leading cause of cancer death worldwide. More than half of NSCLC patients die after developing metastases. There are no tests currently that ...
Mar 11, 2020
0
145
Doctors contemplating the best therapy for lung cancer patients may soon be able to predict the efficacy of a widely used lung cancer drug based on an imaging agent and a simple scan, according to the findings of a new clinical ...
Mar 7, 2018
0
152
Hard to detect in its early stages and hard to treat as it advances, lung cancer is the leading cause of cancer mortality around the world, with an estimated 1.6 million deaths each year. New treatments, however, are bettering ...
Jan 24, 2018
0
164
A new study examines the development of two machine learning models to classify the immunophenotype of a cancer specimen.
Apr 16, 2024
0
0
Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC), according to a study published in the April 11 issue ...
Apr 13, 2024
0
1
